[ad_1]
Original title: Chen Wei’s team finally announced the third phase of this vaccine. Expert: A single injection has high efficiency and is suitable for rapid mass vaccination. Source: World Wide Web
Following the release of Phase III clinical data for two inactivated vaccines from Sinopharm Group, Sinopharm and Kexing Zhongwei, another technical route for the deployment of China’s new corona vaccine is an adenovirus vector developed jointly by the team of the Academician Chen Wei of the Military Academy. Sciences and CanSino Bio The latest data on the Ad5-nCoV vaccine was released on August 8. Pakistani health officials announced on the same day that the interim analysis results of the phase III clinical trial of Ad5-nCoV in Pakistan showed that after a single injection, the vaccine has a 100% protective effect against new coronary pneumonia and serious and global protective effect of 74.8%.
The Ad5-nCoV vaccine developed by Chen Wei’s team is the world’s first new coronavirus vaccine to enter the clinical research stage and is currently one of the only single-dose vaccines in the world to be published. Phase III trial data. Several experts said Global Times Reporters, The effective rate of this vaccine is very good, and the single dose vaccination means that rapid and large-scale population vaccination can be achieved, which is of great importance to the overall prevention strategy of epidemics of society.
Pakistan’s special assistant to the prime minister in charge of national health affairs, Feisuo Sudan, said on the 8th local time that Ad5-nCoV (also known as “Kwisha” or “Convidecia”) conducted an interim analysis of the phase clinical trial. III in Pakistan. 28 days after vaccination, the protective efficacy of the new severe coronary pneumonia vaccine was 100% and the overall protective efficacy was 74.8%. There were no serious adverse reactions related to the vaccine.
The aforementioned officials also revealed that data from the global phase III clinical trial of Ad5-nCoV showed that 28 days after a single injection of the vaccine, the protective efficacy of the vaccine against new severe coronary pneumonia was 90.98 %, and the overall protective efficacy was 90.98%. 65.7%. According to the announcement issued by CanSino Bio on day 1, the phase III clinical trial of Ad5-nCoV has completed the inoculation of more than 40,000 subjects in 78 clinical research centers in 5 countries. Countries where Ad5-nCoV is undergoing phase III clinical trials are reported to include Mexico, Russia, Pakistan, Argentina, and Chile.
Ad5-nCoV was developed by the team of Academician Chen Wei from the Bioengineering Institute of the Academy of Military Medical Sciences of the Academy of Military Sciences and Cansino Bio. The Phase I and Phase II clinical trials were launched in Wuhan on March 16 and April 12 of last year respectively. The world’s first new corona vaccine to enter the clinical research phase. Results of the clinical trial initially demonstrated the safety of the vaccine, and data from the two-phase clinical trials were published in the internationally renowned medical journal “The Lancet.”
A Chinese immunology expert told the Global Times reporter on the 8th that the data for the effective rate of Ad5-nCoV is very good, especially considering it is one of the few new single-dose corona vaccines, in the absence of a second. enhanced effect dose. Therefore, the neutralizing antibody titer is difficult to reach a high level. “If you have to compare horizontally, the effectiveness of Ad5-nCoV should be compared to the data after the first injection of other vaccines.” Professionals in the field of vaccines Zhuang Shili and doctors also told the Global Times reporter the same day, although from the surface The overall efficacy rate of this vaccine appears to be lower than that of several other adenovirus vector vaccines, but should An important prerequisite must be taken into account, that is, the Cansino vaccine is one of the rare single dose vaccines.
Currently, the global and CanSino vaccines using the same technical route to develop also include the Oxford / AstraZeneca vaccine (AZD1222), Johnson & Johnson vaccine (Ad26.COV2.S) and Russia’s “Satellite V” vaccine. which only the CanSino Vaccine and Johnson & Johnson Vaccine Vaccine is a single shot vaccine. On January 29 of this year, Johnson & Johnson announced that the results of the phase III clinical trial of its vaccine showed that 28 days after a single dose of the new corona vaccine, the total effective rate against moderate new coronary pneumonia and severe reached 66%. , prevention of serious diseases in all research areas The effective rate is 85%. On the contrary, although the Johnson & Johnson vaccine is also a single injection, its effectiveness rate of 66% is not mild, and its preventive effect of 85% is not as good as that of Ad5-nCoV 90.98%.
“Specifically, among adenovirus vector vaccines, the data from the Oxford / AstraZeneca vaccine is quite confusing. Overall, the efficiency of the double injection is not high, only 70%; the data from the Russian V-satellite vaccine are relatively optimistic. The injection rate is 91.6%, which is the only adenovirus vector vaccine with an overall effective rate of more than 90%. In addition, according to their article published in The Lancet, the effective rate after first injection of ‘Satellite V’ 73.1% is also a very good figure. In general, the single dose of Cansino vaccine can reach 65.7%, which is a very good result, “said Zhuang Shilihe.
The aforementioned immunology experts analyzed that the single-dose vaccination procedure is straightforward and can inoculate more people in the same time period, which is beneficial in protecting as many people as possible in the shortest time possible. Zhuang Shilihe also believes that Ad5-nCoV can achieve rapid mass vaccination of the population, and the 90% critical illness prevention rate means that the pressure on hospital beds can be greatly reduced. It is understood that another advantage of the Cansino vaccine is that it only needs to be stored between 2 and 8 degrees Celsius, suitable for transport and distribution.
However, the data released by Pakistan this time did not mention whether the efficacy of the Cansino vaccine will be affected by the mutation of the virus. Previously, Johnson & Johnson, AstraZeneca, etc. have reported that the protective efficacy of the vaccine against South African mutant strains has been reduced. In addition, the immunologist interviewed by the Global Times added that it is necessary to continue looking at the adverse reaction data from the Cansino vaccine, because the adenovirus vector vaccine is essentially similar to a cold virus and can cause some cold symptoms during the process of vaccination. It is recommended that people with health problems receive these types of vaccines; you need to keep watching.
